Determination of the maximum tolerated dose of SS2 in mice
| Dose (μg) . | . | Number alive/ total treated . | ||
|---|---|---|---|---|
| Day 10 . | Day 20 . | Day 30 . | ||
| 0 | — | 5/5 | 5/5 | 5/5 |
| 20 | SS2 | 5/5 | 5/5 | 5/5 |
| 40 | SS2 | 5/5 | 5/5 | 5/5 |
| 80 | SS2 | 4/4 | 3/4 | 3/4 |
| 10 | Monomer | 4/4 | 4/4 | 3/4 |
| 20 | Monomer | 1/4 | 0/4 | 0/4 |
| 40 | Monomer | 0/4 | 0/4 | 0/4 |
| Dose (μg) . | . | Number alive/ total treated . | ||
|---|---|---|---|---|
| Day 10 . | Day 20 . | Day 30 . | ||
| 0 | — | 5/5 | 5/5 | 5/5 |
| 20 | SS2 | 5/5 | 5/5 | 5/5 |
| 40 | SS2 | 5/5 | 5/5 | 5/5 |
| 80 | SS2 | 4/4 | 3/4 | 3/4 |
| 10 | Monomer | 4/4 | 4/4 | 3/4 |
| 20 | Monomer | 1/4 | 0/4 | 0/4 |
| 40 | Monomer | 0/4 | 0/4 | 0/4 |
C57BL/6 mice were randomly divided into groups (n = 4-5 per group) and injected with varying concentrations of SS2 given intraperitoneally and twice a day on days 0 to 3. Data are expressed as number of survivors per number of mice treated. Mice were observed for at least an additional 30 days with no change in survival.